Palvella Therapeutics, Inc. (PVLA) Stock Score, Valuation & Financial Research

Palvella Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PVLA

Palvella Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 122.58. These figures are a research snapshot, not a buy or sell recommendation.

What Palvella Therapeutics, Inc. does

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Palvella Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel topical therapies for serious, rare skin diseases and vascular malformations using its proprietary QTORIN platform, with the goal of achieving future regulatory approvals and commercialization.

Products and services

  • The company is developing a pipeline of product candidates based on its patented QTORIN platform, including its lead candidate, QTORIN 3.9% rapamycin, which is designed to deliver therapeutic agents to deep skin layers with minimal systemic absorption.

Brands and product families

  • QTORIN — Proprietary platform for topical delivery of therapeutic agents. Source

Customer types

Patients with serious, rare skin diseases and vascular malformations.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, data collection, and the manufacturing of clinical trial materials. Specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary QTORIN platform technology Source
  • Experienced management team in rare disease biotechnology Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on successful clinical trial results and regulatory approval Source
  • Reliance on third-party manufacturers and clinical trial service providers Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PVLA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 122.58
Market capitalization:
1.77B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -61.7M
Free cash flow:
USD -25.01M
Cash:
USD 187.8M
Total debt:
USD 535K
EPS:
USD -4.83

What stands out

  • Free cash flow is USD -25.01M, negative for the stored period.
  • The balance sheet shows USD 187.8M of cash versus USD 535K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 187.27M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PVLA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PVLA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PVLA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PVLA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PVLA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research PVLA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.